In response to the combination therapy, we find that tumor cells increase production of CCL9, which is associated with greater mobilization of G-MDSCs out of the bone marrow and into the tumor bed, which could be limited by CCR1 inhibition. This evidence concerns the gene CCR1 and neoplasm.